Table 3.

Characteristics of surviving patients

pt #	age	sex	diagnosis	year of initial dx	year of recurrence	primary site	metastasis or recurrence at enrollment	Cytoreductive therapy	status post frontline chemotherapy	IL-2	T cells (×106)/kg	completed Rx	immune response	OS (years)	Follow Up
New Dx with metastasis
3	16	M	AR	1998	NA	Bladder	bladder, lymph nodes, bone marrow	chemo, SCT, XRT	CR	mod	124.4	y	+	9.2	NED*
13	33	M	ESFT	2000	NA	L femur	L femur with pulmonary mets	chemo, XRT	CR	low	207.2	y	−	7.2	NED*
29	11	F	ESFT	2002	NA	R fibula	R fibula & pulmonary	chemo, XRT	CR	none	99.6	y	−	5.3	NED*
Recurrence (>1yr after frontline therapy)
22	18	F	AR	1998	2000	R neck/sinus	breast	chemo, SX	CR	low	153.3	y	−	7.3	NED*
6	39	M	ESFT	1983	1998	10th L rib	R diaphragm	chemo, SX	PR	mod	108.9	y	+	9.7	recurred; currently NED × one year
10	3	F	AR	1995	1998	R orbit	R pre-auricular LN	SX, chemo, SCT	PD	mod	249.6	n	+	9.4	disease progression during immunotherapy, currently NED for > 5 years
11	28	M	ESFT	1980	1998	L tibia	pulmonary mets	chemo	CR	mod	74.0	y	+	9.4	recurred; currently NED for > 3 years
5	16	F	ESFT	1995	1998	R thigh	kidney	chemo	CR	mod	203.0	y	+	9.1	NED*
16	21	M	ESFT	1991	2001	Neck	neck	chemo	CR	low	141.7	y	−	6.6	NED*
20	6	F	AR	1997	2000	L ankle	s/p resection of local recurrence	chemo	CR	low	244.5	y	−	7.8	NED*
27	26	F	ESFT	1994	2002	R arm	R clavicle/L pleural mass with rib/pulmonary	XRT, chemo	PR	none	197.2	y	−	5.1	recurred; currently NED for > 3 years

Abbreviation: dx, diagnosis; NA, not applicable; LN, lymph node; SX, surgery; SCT, stem cell transplant; XRT, radiation treatment; CR, complete response; PR, partial response; PD, progression of disease; IL-2, interleukin 2; mod, moderate; OS, overall survival; AWD, alive with disease; NED, no evidence of disease.

^*NED since initiating immunotherapy